Vosoritide
Aliases: Voxzogo
Last verified: 2026-09-23
The short version
A C-type natriuretic peptide (CNP) analogue — the first drug to increase bone growth in achondroplasia (the most common dwarfism) in children.
Identity & type
- Molecular type
- analog
- Origin
- A C-type natriuretic peptide (CNP) analogue — the first drug to increase bone growth in achondroplasia (the most common dwarfism) in children.
Mechanism of action
NPR-B agonism → suppression of hyperactive FGFR3 signaling → normalized chondrogenesis.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Weight-based SC daily while growth plates open.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Weight-based SC daily while growth plates open. Voxzogo: measurable extra growth (~1.5 cm/yr more) in children with achondroplasia; parents report good tolerability.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Voxzogo: measurable extra growth (~1.5 cm/yr more) in children with achondroplasia; parents report good tolerability.
Protocol — official vs community
Official / label
Voxzogo, for achondroplasia in children with open epiphyses: weight-based SC once daily — 0.24 mg/kg for 15 to <60 kg, and a fixed 15 mg for ≥60 kg — at a consistent time each day, after a light meal.
- 01Day 1 (initiation): dose escalation in supervised steps (0.05 mg/kg → 0.1 mg/kg → final dose) to test tolerability
- 02After ≥12 months: may increase to 0.28 mg/kg in inadequate responders who tolerated therapy
Duration: Daily until growth plates close (end of puberty); phase 3 added ~1.57 cm/year of growth versus placebo.
CNP analogue that counteracts overactive FGFR3 signaling in the growth plate. Transient hypotension right after injection is the characteristic adverse effect — hence the light meal and consistent-timing instructions.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Phase III: +1.57 cm/year extra growth vs placebo.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Injection-site reactions, transient hypotension.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials